New treatments outperforming placebo becoming less common

New treatments outperforming placebo becoming less common
The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

(HealthDay)—The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of Health Affairs.

Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and Steven C. Marcus, Ph.D., from the University of Pennsylvania in Philadelphia, randomly selected and analyzed 315 placebo-controlled trials published in BMJ, the Journal of the American Medical Association, The Lancet, and the New England Journal of Medicine from 1966 to 2010.

The researchers found that the average effect size or average difference in efficacy fell significantly between the active treatment and placebo, from a peak odds ratio of 4.51 (1971 to 1980) to 1.36 (2001 to 2010).

"A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy," Olfson and colleagues conclude.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Placebo often effective for treating headache in children

date Jan 29, 2013

(HealthDay)—Placebo is often effective in treating children with headaches, and innovative strategies are needed to reduce the placebo response rate and prove drug effects in trials, according to two studies ...

Collagenase clostridium histolyticum OK in Peyronie's

date Apr 26, 2013

(HealthDay)—For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online ...

Imeglimin beneficial as add-on to metformin in T2DM

date Dec 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, ...

Recommended for you

India's bidi workers suffer for 1,000-a-day habit

date 12 hours ago

Zainab Begum Alvi and her band of young helpers hunch over baskets filled with tobacco flakes and dried leaves, trying to roll a thousand dirt-cheap cigarettes a day at the behest of India's powerful bidi barons.

Key to better sex ed: Focus on gender & power

date Apr 17, 2015

A new analysis by Population Council researcher Nicole Haberland provides powerful evidence that sexuality and HIV education programs addressing gender and power in intimate relationships are far more likely ...

Journal tackles aging policy issues raised by White House

date Apr 17, 2015

In anticipation of the forthcoming 2015 White House Conference on Aging (WHCoA), The Gerontological Society of America (GSA) has produced a special issue of The Gerontologist that outlines a vision for older adults' econom ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JRi
Jun 15, 2013
Probably something to do with more strict guidelines, how tests need to be carried out nowadays. Laws require to inform authorities in advance when starting new tests. More difficult for pharmaceutical companies to "forget" the trials that failed to give positive outcome.
Wolf358
Jun 15, 2013
Maybe it's all of the new improved extra-strength placebos....

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.